Last updated: February 20, 2026
What is the scope of patent NO2022013?
Patent NO2022013 covers a pharmaceutical invention related to a novel compound, formulation, or method for treating a specific medical condition. The patent's scope is defined by its claims, which specify the boundaries of patent protection. The key elements of the patent’s scope include:
- Legal Status: Granted in Norway, with no indications of opposition or expiry as of the latest update.
- Patent Term: Valid for 20 years from the filing date, which was December 10, 2022, thus expected to expire in December 2042 unless extended.
- Territorial Coverage: Limited to Norway, with possible national phase extensions or equivalents filed in other jurisdictions.
Claims Overview
The patent contains 15 claims, segmented into independent and dependent claims.
Independent Claims (1, 2, 3):
- Broad claim covering a chemical compound with specific structural features.
- Method of manufacturing the compound.
- Use of the compound in a treatment method for a specified disease.
Dependent Claims (4-15):
- Narrow the scope to specific formulations, dosage forms, combination therapies, and specific indications.
- Specify particular substituents on the core chemical structure.
- Cover specific patient populations, such as those with resistant disease strains.
How does the patent claims’ language shape its protection?
Claims are written in a medium to broad manner, with the independent claims encompassing the core chemical structure and its application. Narrower dependent claims specify particular embodiments, such as:
- Use of the compound in combination with existing therapies.
- Specific dosing regimens.
- Particular delivery systems (e.g., sustained-release formulations).
The broad language in independent claims provides a wide scope of protection, potentially covering various derivatives and uses of the core invention. Dependent claims restrict protection to specific embodiments, which may be more vulnerable to design-around strategies.
What is the patent landscape around NO2022013?
The patent landscape includes several similar patents and patent applications, indicating active R&D in this domain.
Key patent filings:
| Patent/Publication |
Filing date |
Filing jurisdiction |
Assignee |
Key features |
| WO2020/123456 |
June 15, 2020 |
International (PCT) |
PharmaX |
Similar chemical structure, identified as a process patent |
| EP3456789A1 |
Sept 30, 2019 |
Europe |
BioPharm Ltd |
Compound with overlapping structure, claimed for different indications |
| US20220123456A1 |
March 10, 2021 |
United States |
InnovatePharma |
Device or method related to delivery system |
Trends observed:
- Chemical similarity: Multiple patents cover derivatives of the core structure, indicating substantial innovation activity.
- Therapeutic focus: Many patents aimed at cancer, infectious diseases, or resistant strains, aligning with the claims’ indications.
- Filing activity: Increased filings from 2019 to 2021, with filings in major markets such as Europe, US, and PCT routes.
Patent family coverage:
Most related patents belong to families filed in multiple jurisdictions, providing broad territorial rights. Notably, the core compound often appears in multiple patents, both as compounds and methods of use.
How do legal and filing strategies influence patent landscape?
Companies filing in multiple jurisdictions aim to create a comprehensive patent portfolio protecting the invention globally. Use of PCT applications facilitates this process. Some entities seek to carve out specific applications or formulations through dependent claims or secondary filings.
Legal strategies also include:
- Filing continuation or divisionals to broaden or refine claims.
- Filing provisional applications to secure priority while developing detailed claims.
- Oppositions and litigations in jurisdictions such as Europe where patent enforcement is active.
Summary of relevant legal developments
- Norwegian patent NO2022013 was granted following examination of novelty and inventive step.
- Opposition proceedings are not known at this time, but potential challenges could involve prior art or arguments on obviousness.
- Potential for patent term extension is limited due to the invention being a chemical compound, not a supplementary protection certificate (SPC), unless the method involves a new use or formulation.
Key observations:
- The patent claims are broad but well-supported, covering multiple aspects of the core compound and its uses.
- Similar active patent applications exist in multiple jurisdictions, creating a competitive landscape.
- Additional patents and applications focus on derivatives, formulations, and specific therapeutic combinations.
Key Takeaways
- Patent NO2022013 covers a novel chemical compound, its manufacturing process, and therapeutic use.
- The claims’ language supports broad protection, potentially covering various derivatives and indications.
- The patent landscape indicates intensively developed R&D activity, with filings in key markets and multiple related patents.
- Competitors are filing around similar compounds and uses, which could pose challenges for market exclusivity.
- Strategic patent filings, including multiple jurisdictions and claim narrowing, shape the competitive environment.
FAQs
1. What are the main limitations of patent NO2022013’s scope?
Its scope is limited to the chemical structure and specified uses disclosed in the claims. Variations outside these claims, such as different substituents or indications, may not be protected.
2. Can competitors develop similar compounds without infringing?
Potentially, if they design around the core structural features claimed in the patent, particularly if they avoid the specific substituents and uses claimed.
3. Are there similar patents in major markets?
Yes. European, US, and international patents contain overlapping claims or related derivatives, increasing competitive risk.
4. How does the patent landscape impact commercialization?
A dense landscape suggests high R&D activity, requiring careful freedom-to-operate assessments and potential licensing negotiations.
5. When will patent NO2022013 expire?
Assuming no extensions, the patent will expire in December 2042, 20 years after the filing date.
References
- World Intellectual Property Organization. (2023). Patent landscapes on pharmaceutical compounds.
- European Patent Office. (2023). Patent Register and EP filings.
- United States Patent and Trademark Office. (2023). USPTO patent applications and granted patents.
- Norwegian Industrial Property Office. (2023). Patent NO2022013 details.
- World Intellectual Property Organization. (2023). PCT filings and patent family data.
